A groundbreaking new study has found that a combination of two drugs can boost survival rates in prostate cancer patients by ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy.

New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...

A new trial will look at whether selecting patients who may require more intensive treatment can improve outcomes for advanced prostate cancer.

A simple blood test may help doctors decide the best way to treat a man with advanced prostate cancer. A phase 3 clinical trial has shown that circulating tumor cell (CTC) counts can predict which men ...

Approximately half of men with metastatic castration-resistant prostate cancer and BRCA1 or BRCA2 mutations do not receive medications that could improve their survival.Poly (adenosine ...

EDITOR’S NOTE: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine. President Joe Biden’s ...

February 26, 2007 — A blood test for C-reactive protein (CRP), which is readily available and already used to assess the risk of cardiovascular disease, could be useful in predicting prognosis for men ...

Former US president Joe Biden could have just years left to live given how his prostate cancer is aggressive, has spread and was caught late, data suggests. The 82-year-old's diagnosis was announced ...

The testosterone threshold should be less than 10 ng/dL rather than less than 50 ng/dL for gauging advanced prostate cancer prognosis in patients on ADT. Examining sustained testosterone suppression ...

A community-based (real-world) study showed that artificial intelligence (AI)-informed analysis of screening mammograms ...